Haemonetics Corporation has entered into a definitive agreement to acquire Attune Medical, the manufacturer of the ensoETM proactive oesophageal cooling device, the only US Food and Drug Administration (FDA)-cleared temperature regulation device indicated for oesophageal protection during radiofrequency (RF) cardiac ablation procedures.
Under the terms of the agreement, Haemonetics will acquire Attune Medical for an upfront cash payment of US$160 million at closing plus additional contingent consideration based on sales growth in the three years following the consummation of the transaction and the achievement of certain other milestones. The acquisition is subject to customary closing conditions and is expected to be completed in the first quarter of Haemonetics’ fiscal year 2025.
In the treatment of atrial fibrillation (AF), ensoETM is designed to significantly reduce the likelihood of oesophageal injury during RF cardiac ablations. Additionally, studies have reported reduced procedure times and patient readmissions, and increased rates of same-day discharge and long-term procedure success with the use of ensoETM.
Jay Istvan, chief executive officer at Attune Medical, said: “We are thrilled to become part of Haemonetics. Their Hospital business has strong positions in both EP and critical care, and their international channels are robust and expanding. We believe Haemonetics is the best company to bring ensoETM’s substantial benefits to more caregivers worldwide to enable new standards of care.”
Haemonetics Corporation recently completed the acquisition of OpSens, a manufacturer of technologies primarily for use in interventional cardiology.
